Comparative pharmacokinetic analysis of the blood-brain barrier penetration of dasatinib and ponatinib in mice
Karthik Ravi, Andrea Franson, Morgan J. Homan, Holly Roberts, Manjunath P. Pai, Zachary Miklja, Miao He, Bo Wen, Lydia L. Benitez, Anthony J. Perissinotti, Dale L. Bixby, Carl Koschmann, Bernard L. Marini
Abstract
The use of tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL fusion protein have dramatically changed the clinical management and outcomes for patients with chronic myelogenous leukemia (CML)...
Topics & Concepts
DasatinibPonatinibChronic myelogenous leukemiaMedicineImatinibTyrosine kinasePharmacokineticsTyrosine-kinase inhibitorPharmacologyNilotinibLeukemiaCancer researchOncologyInternal medicineMyeloid leukemiaReceptorCancerChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia ResearchAcute Lymphoblastic Leukemia research